# Nusano **Type:** venture **Status:** Draft **Confidence:** Medium **Focus:** medical radioisotopes, radiopharmaceuticals, accelerator physics, isotope supply chain, oncology, advanced manufacturing **Stage:** Private; Series C raised, flagship facility operational (opened August 2025) **Location:** West Valley City, UT **Updated:** 2026-06-18 **Needs-reviewed:** 2026-06-18 **Hero:** https://picsum.photos/seed/nusano-radioisotope-accelerator-2026/1600/1100 **Pull:** *Building domestic supply for the radioisotopes that next-generation cancer drugs depend on.* ## Summary Nusano is a physics company building a new way to produce medical and industrial radioisotopes. In August 2025 it cut the ribbon on a 190,000-square-foot radioisotope production facility in West Valley City, Utah, with Utah Governor Spencer Cox attending. The company says the site is designed to make more than 40 different radioisotopes — and up to 12 simultaneously — anchored by a proprietary ion-source and particle-acceleration platform. [source:nusano-official-website] For the Great Work Utah wiki, Nusano is a rare hard-tech bet sitting at the intersection of accelerator physics, advanced manufacturing, oncology, and national supply-chain security — and it is being built in Utah from scratch. ## Impact Radiopharmaceuticals — drugs that deliver radiation directly to cancer cells while sparing healthy tissue — are one of the most active frontiers in oncology, with isotopes such as lutetium-177 and actinium-225 central to emerging therapies. The field is bottlenecked by isotope supply: much production depends on a small number of aging reactors and fragile international supply chains, where a single outage can disrupt clinical programs. Nusano's impact mechanism is enabling infrastructure. If it succeeds, the constraint on radiopharmaceutical development shifts from "can we get the isotope?" toward "does the drug work?" — which can unblock many downstream clinical programs. A secondary impact is national security: reducing US dependence on foreign isotope suppliers. ## What They Are Building The core technology is a proprietary ion source that Nusano says creates heavy ions at rates far higher than existing commercial systems, feeding a particle-acceleration platform tuned for high-volume, high-quality (cGMP-grade) isotope production. The West Valley City facility is the company's flagship, with production slated to begin in late 2025 and to ramp toward the full 40-plus isotope menu under full operations. Public coverage indicates Nusano has begun lining up demand and partnerships — for example, a lutetium-177 supply agreement reported with Australian targeted-radiotherapy company GlyTherix — and that the site is expected to expand the company's actinium-225 production capacity substantially. Beyond healthcare, Nusano has described industrial applications such as long-lived nuclear batteries. [source:nusano-official-website] ## What They Need Now Likely needs include accelerator physicists, radiochemists, nuclear and target engineers, cGMP manufacturing-process engineers, quality and regulatory staff spanning both nuclear and pharmaceutical regimes, and commercial leaders to convert reservations into long-term supply agreements. This is hands-on, heavily regulated, technically demanding work. For talent matching, Nusano fits physicists, chemists, and engineers who want a direct line from bench work to patient outcomes, and who are drawn to building first-of-its-kind production capability rather than incremental product work. ## Who Could Help Useful helpers include regulatory counsel fluent in both nuclear licensing and FDA/pharma requirements, radiopharma commercial and business-development partners, logistics specialists who can move short-half-life material reliably, and investors comfortable with capital-intensive hard tech. Utah's economic-development apparatus is already engaged given the Governor's participation in the facility opening. ## Utah Context Nusano adds a genuinely unusual capability to Utah's industrial base: large-scale accelerator-driven isotope production tied directly to the oncology drug pipeline and to domestic supply-chain resilience. The state's participation in the August 2025 opening signals that Utah views this as strategically important infrastructure. Alongside companies like [Merit Medical](merit-medical.md) and BioFire on the device and diagnostics side, Nusano broadens the state's life-sciences story into nuclear medicine and advanced manufacturing. ## Evidence - [Source: Nusano Official Website and Facility-Opening / Series C Announcements](nusano-official-website.md) ## Open Questions - Earlier internal framing treated Nusano's ownership as opaque; public sources now confirm a Series C round announced in October 2024 with funding commitments of over $115M. Full investor identities, total capital raised since, and control structure are still not fully public. - Whether the broad 40-plus isotope mission holds depends on whether any single pharma partner captures the roadmap; the GlyTherix Lu-177 agreement and Ac-225 focus are leads, not the full commercial picture. - Production timelines ("late 2025," "full operations") come largely from company statements and press coverage; actual output volumes and cGMP qualification status should be verified before strong claims. - Headquarters history is mixed in sources (early materials cite Valencia, California; later coverage describes Nusano as Utah-headquartered). The current corporate HQ and the West Valley City site's role should be confirmed. - Imagery is a deterministic placeholder. A license-cleared photograph of the facility or accelerator equipment approved by the company should replace it before this renders as a marquee page.